title: Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor.
abstract: The therapeutic effect of a combined modality of lymphokine-activated killer (LAK) cells and tumor necrosis factor alpha (TNF alpha) on MBL-2 tumor in C57BL/6 mice was studied. Murine LAK cells induced from splenocytes by interleukin 2 (IL2) could lyse MBL-2 target cells in vitro. but no enhancement of the LAK activity was found by the treatment of LAK cells with TNF alpha in vitro. However, the treatment of MBL-2 with TNF alpha enhanced the sensitivity to LAK cells. Moreover, administration of TNF alpha to mice bearing solid MBL-2 tumor led to increased tumor vascular permeability within 1 h, and resulted in the enhanced accumulation of systemically transferred LAK cells in tumor tissue. Based on these results, we treated MBL-2-bearing mice with TNF alpha and then with LAK cells 1 h later. No therapeutic effect was observed when tumor-bearing mice were treated with TNF alpha alone or LAK cells plus IL2. However, adoptive immunotherapy using LAK cells and TNF alpha had therapeutic effects, i.e., growth inhibition of tumor nodules and prolongation of survival. These results indicated that appropriately timed pretreatment of tumor-bearing mice with TNF alpha augmented the anti-tumor efficacy of LAK cells.
authors.affiliation: Department of Hygienic Chemistry, Pharmaceutical Institute, Tohoku University, Sendai.
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: T
authors.initials: T
authors.lastname: Tanabe
authors.forename: T
authors.initials: T
authors.lastname: Agatsuma
authors.forename: S
authors.initials: S
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Nitanai
authors.forename: Y
authors.initials: Y
authors.lastname: Hashimoto
mesh_terms: D000818:Animals; D002199:Capillary Permeability; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008979:Moloney murine leukemia virus; D016260:Monocytes, Activated Killer / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
chemical_list: D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha